Compare · ARGX vs HUMA
ARGX vs HUMA
Side-by-side comparison of argenx SE (ARGX) and Humacyte Inc. (HUMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and HUMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 178.7x HUMA ($306.4M).
- Over the past year, ARGX is up 51.2% and HUMA is down 46.4% - ARGX leads by 97.6 points.
- HUMA has been more active in the news (7 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for HUMA).
- Company
- argenx SE
- Humacyte Inc.
- Price
- $882.63-1.03%
- $1.38+1.85%
- Market cap
- $54.76B
- $306.4M
- 1M return
- +12.11%
- +27.31%
- 1Y return
- +51.24%
- -46.39%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest HUMA
- Humacyte Inc. filed SEC Form 8-K: Other Events
- Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Director Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)
- Director Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)
- CFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Parikh Shamik J sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 272,713 units (SEC Form 4) (for withholding tax)
- Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- SEC Form S-8 filed by Humacyte Inc.
- SEC Form 10-Q filed by Humacyte Inc.
- Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update